ZOLL LifeVest

A Proven Therapy for Patients at Risk of Sudden Cardiac Death

See How LifeVest^® Works

ZOLL LifeVest

A Proven Therapy for Patients at Risk of Sudden Cardiac Death

See How LifeVest^® Works

Extensive clinical evidence demonstrates the safe and effective use of LifeVest.

Review Clinical Results

Ordering LifeVest

There are several ways to order LifeVest for your patients. In each case, documentation is required to support the diagnosis.

Learn More

LifeVest Network

ZOLL’s online patient data management system provides actionable insights during recovery after a cardiac event.

Learn More

A Deeper Dive into the VEST Trial: Results of the new 2020 analysis

See the data

Guideline Recommendations

The WCD is recommended for ICM and NICM patients following a cardiac event (Class IIb-NR).

Learn More

Insurance Coverage

Most commercial, state, and federal plans cover LifeVest. See which patients types are commonly covered.

Learn More

Find answers to commonly asked questions about the LifeVest wearable defibrillator.

Read the FAQs

See how LifeVest works by watching a LifeVest patient treatment ECG

First Responder Resources

View or download educational resources for paramedics, fire fighters, police officers, and other first responders.

Learn More

WCD Education

View wearable cardioverter defibrillator education programs online, including CME programs.

Learn More

Patient Support Materials

Resources are available to download and share with your patients.

Learn more

Following a cardiac event, risk of SCD is highest in the first 90 days^1,2
¹Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581–2588.
²Adabag AS, Therneau TM, Gersh BJ, et al. Sudden death after myocardial infarction. JAMA. Circulation 2008;300(17):2022–2029.

Despite PCI & GDMT, 1 in 20 post-MI (EF≤35%) patients die in the first 90 days³
³Olgin JE, Pletcher MJ, Vittinghoff E, et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018;379(13):1205–1215.

SCD accounts for ~50% of mortality following an MI, PCI, or new HF diagnosis (EF≤35%)^4,5
⁴Olgin JE, Pletcher MJ, Vittinghoff E, et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018;379(13):1205–1215.
⁵Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334(21):1349–1355.